Investor
First Light Asset Management, LLC
CIK 0001600004 · filed 2026-05-15 · SEC filing
13F book
$1.12B
Positions
35
7 new · 5 sold
Largest name
11.9%
Axogen, Inc. · AXGN
Est. mark
−$119.6M
Price effect on 28 names still held. Flow −$72.5M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Axogen, Inc. | AXGN | 4M | $132.6M | 11.9% | $1.6M | Cut−$38.7M |
| Palvella Therapeutics Inc Ne | — | 980.8K | $122.3M | 11.0% | $14.2M | Added$48M |
| Neogenomics Inc | NEO | 9.73M | $72.2M | 6.5% | −$42.2M | Cut−$45.8M |
| SI-BONE, Inc. | SIBN | 5.35M | $67.6M | 6.1% | −$35.7M | Added−$31.6M |
| Centessa Pharmaceuticals Plc | — | 1.56M | $62M | 5.6% | $23M | Cut$5.01M |
| Apogee Therapeutics, Inc. | APGE | 576.7K | $48.5M | 4.3% | $2.48M | Added$27M |
| Amylyx Pharmaceuticals, Inc. | AMLX | 3.19M | $44.3M | 4.0% | $5.81M | Cut$3.82M |
| Twist Bioscience Corp | TWST | 878.8K | $41.8M | 3.7% | $13.9M | Cut$5.58M |
| Crinetics Pharmaceuticals In | — | 1.09M | $39.6M | 3.5% | −$11.1M | Cut−$16M |
| 908 Devices Inc. | MASS | 6.07M | $37.2M | 3.3% | $4.21M | Added$11.8M |
| Neuropace Inc | NPCE | 2.46M | $32.3M | 2.9% | −$3.09M | Added$11.5M |
| Edgewise Therapeutics, Inc. | EWTX | 1M | $31.6M | 2.8% | $6.7M | Cut−$7.49M |
| Anaptysbio, Inc | ANAB | 565.4K | $31.4M | 2.8% | $3.95M | Cut$29.2K |
| Simulations Plus, Inc. | SLP | 2.63M | $31.1M | 2.8% | −$12.6M | Added−$4.77M |
| Guardant Health, Inc. | GH | 280.3K | $25.9M | 2.3% | −$2.74M | Cut−$4.21M |
| Tandem Diabetes Care Inc | TNDM | 1.31M | $25.2M | 2.3% | −$3.06M | Added$1.26M |
| AtriCure, Inc. | ATRC | 729.5K | $20.8M | 1.9% | −$8.05M | Cut−$25.7M |
| Trisalus Life Sciences Inc | — | 5.07M | $20.3M | 1.8% | — | New |
| Tectonic Therapeutic, Inc. | TECX | 647.7K | $20M | 1.8% | — | New |
| Irhythm Technologies Inc | IRTC | 168.1K | $19.8M | 1.8% | −$9.14M | Added−$7.46M |
| Septerna, Inc. | SEPN | 732.9K | $17.6M | 1.6% | −$2.39M | Added$302.4K |
| Establishment Labs Hldgs Inc | — | 307.7K | $17.5M | 1.6% | −$4.95M | Cut−$9.72M |
| Health Catalyst, Inc. | HCAT | 12.9M | $16.4M | 1.5% | −$14.4M | Cut−$14.5M |
| Omnicell, Inc. | OMCL | 489.8K | $16.4M | 1.5% | — | New |
| KORU Medical Systems, Inc. | KRMD | 3.77M | $16.3M | 1.5% | −$5.61M | Cut−$8.18M |
| GeneDx Holdings Corp. | WGS | 242.9K | $15.6M | 1.4% | — | New |
| Wave Life Sciences Ltd. | WVE | 1.84M | $13.4M | 1.2% | −$18M | Cut−$18.1M |
| Vera Therapeutics, Inc. | VERA | 313.9K | $12.6M | 1.1% | −$3.27M | Cut−$31.4M |
| Mimedx Group, Inc. | MDXG | 2.84M | $11.2M | 1.0% | −$8.02M | Cut−$9.35M |
| Butterfly Network, Inc. | BFLY | 2.66M | $10.7M | 1.0% | $638.4K | Cut$61K |
| SpyGlass Pharma, Inc. | SGP | 375K | $9.72M | 0.9% | — | New |
| Organogenesis Hldgs Inc | — | 3.5M | $8.29M | 0.7% | −$9.83M | Cut−$11.7M |
| Vaxcyte, Inc. | PCVX | 141.8K | $8.24M | 0.7% | — | New |
| Enliven Therapeutics, Inc. | ELVN | 201.9K | $7.91M | 0.7% | — | New |
| Rhythm Pharmaceuticals, Inc. | RYTM | 87.2K | $7.58M | 0.7% | −$1.75M | Cut−$24.1M |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.